Skip to main content
. 2019 Apr 13;85(8):1781–1789. doi: 10.1111/bcp.13965

Figure 5.

Figure 5

Vascular endothelial growth factor (VEGF)‐A changes predicts benefit from cediranib: Individual examples. VEGF‐A demonstrated 2 distinct patterns of trajectories following cediranib and the patterns can be used to predict treatment benefit from cediranib. Patients with elevated VEGF‐A concentrations in the first 3 cycles of treatment have significantly improved progression‐free survival (PFS) over those with decreased or stable VEGF‐A concentration. Examples of the former were given in the left panel, where patients demonstrated longest PFS (1014, 1042 and 731 respectively), while example of the latter can be found in the right panel, where patients had moderate PFS (270, 364 and 237 respectively)